Clinical Trials Logo

Anaplastic Lymphoma clinical trials

View clinical trials related to Anaplastic Lymphoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT04908059 Recruiting - Anaplastic Lymphoma Clinical Trials

Leukemic Phase of ALCL

LEUK-ALCL
Start date: January 27, 2021
Phase:
Study type: Observational

Collecting data about the rare leukemic presentation of anaplastic lymphoma to study the characteristics of patients with leukemic phase of ALCL

NCT ID: NCT04828174 Suspended - Clinical trials for Angioimmunoblastic T-cell Lymphoma

Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies

Start date: March 31, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of CAR T cell treatment targeting TRBC1 in patients with relapsed or refractory TRBC1 positive T-cell hematological maliganacies

NCT ID: NCT03971305 Recruiting - Pediatric Cancer Clinical Trials

A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL

Start date: May 5, 2017
Phase:
Study type: Observational [Patient Registry]

With the development of molecular biology and precise medical treatment, new challenges have been raised in the diagnosis and treatment of non-Hodgkin lymphoma (NHL) in children. In recent years, the criteria for clinical staging and efficacy evaluation of NHL in children have been updated. Studies in Germany and the United States have shown that pathological types of systemic anaplastic large cell lymphoma (ALCL) in children and adolescents, minimal disseminated disease (MDD) in peripheral blood or bone marrow and minimal residual disease (MRD) are significantly associated with prognosis, suggesting that these factors need to be combined in risk stratification of ALCL patients. Recent studies have also suggested that PET/CT is helpful in evaluating residual lesions in patients with lymphoma after chemotherapy. In order to keep pace with the times in the diagnosis, clinical staging, risk stratification, efficacy evaluation and treatment of NHL in children. We adjusted the original NHL-BFM-90/95 regimen, mainly in the aspects of clinical staging, efficacy evaluation, risk stratification and treatment regimen,etc.